The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2-The results of ProBCG: a multicenter randomized clinical trial in Brazil.
Journal Information
Full Title: Int J Infect Dis
Abbreviation: Int J Infect Dis
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Communicable Diseases
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declaration Of Competing Interest The authors have no competing interests to declare."
"Funding The study was funded by 10.13039/501100004809FINEP – Public Funding Agency for Innovation and Research – linked to the Ministry of Science, Innovation and Technology of Brazil (grant number 01.20.0012.00). Mello FCQ was supported by 10.13039/501100005993National Council for Scientific and Technological Development (CNPq) (grant number 306057/2020-4) and by the 10.13039/501100004586Foundation for Research Support in the State of Rio de Janeiro – State Scientist Program (grant call #18/2022)."
"Ethics ApprovalThe Brazilian National Ethics Committee of Research approved the study under protocol # 4.089.065. The trial was registered on ClinicalTrials.gov under #NCT04659941. Conclusion: Our results suggest that BCG has a tendency of protection against SARS-CoV-2 and higher immunoglobulin G levels than placebo. The clinical trial was registered at https://clinicaltrials.gov/ (NCT04659941)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025